Trials & Filings
Related Searches:
Filter by:
31 - 45 of 604 results
April 15, 2011
Pfizer achieved positive results from the ORAL Scan Phase III study of tofacitinib, an investigational oral JAK inhibitor, in patients with moderate-to-severe active rheumatoid arthritis (RA) who had an inadequate response to methotrexate (MTX).
Read More »
April 15, 2011
Galapagos NV will discontinue its Phase II trial for GLPG0259 in rheumatoid arthritis (RA) following a planned interim analysis that did not support continuing development of the drug for RA.
Read More »
April 12, 2011
Novartis AG is discontinuing development of Tasigna as a treatment for cancerous tumors of the gastrointestinal tract.
Read More »
April 11, 2011
Biogen Idec achieved positive results from DEFINE, a Phase III trial to evaluate the investigational oral compound BG-12 (dimethyl fumarate) as a monotherapy in people with relapsing-remitting multiple sclerosis (RRMS).
Read More »
April 11, 2011
Johnson & Johnson received approval from the FDA for Invega (paliperidone) extended-release tablets for the treatment of schizophrenia in adolescents 12 to 17 years of age.
Read More »
April 7, 2011
GlaxoSmithKline and XenoPort, Inc. received approval from the FDA for Horizant (gabapentin enacarbil) Extended-Release Tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).
Read More »
April 4, 2011
Avanir Pharmaceuticals, Inc. has filed an IND application with the FDA to begin a large Phase II trial of AVP-923, an investigational drug for the treatment of central neuropathic pain in patients with multiple sclerosis (MS).
Read More »
March 21, 2011
Novartis received approval from the European Commission for Gilenya (fingolimod) 0.5 mg daily pill for the treatment of highly active relapsing-remitting multiple sclerosis (RRMS).
Read More »
March 21, 2011
Genentech’s Phase II study of its investigational Hedgehog Pathway Inhibitor, vismodegib (RG3616/GDC-0449), showed positive results in people with advanced basal cell carcinoma (aBCC), a severe form of skin cancer.
Read More »
March 16, 2011
RegeneRx Biopharmaceuticals, Inc. has received a notice from the FDA indicating that, due to non-compliance with cGMP regulations by its contract manufacturer, the company’s Phase II trial of RGN-352 has been placed on clinical hold.
Read More »
March 15, 2011
Incyte Corporation’s COMFORT-II, the second Phase III trial of investigational Janus kinase (JAK) inhibitor, ruxolitinib, has met its primary endpoint of significantly reducing spleen size in patients with myelofibrosis.
Read More »
March 11, 2011
Tolerx and GlaxoSmithKline’s Phase III DEFEND-1 study of otelixizumab, an investigational humanized anti-CD3 monoclonal antibody, did not meet the primary efficacy endpoint in patients with new-onset autoimmune type 1 diabetes.
Read More »
March 11, 2011
Sanofi-aventis and Regeneron Pharmaceuticals’ Phase III VITAL trial evaluating the investigational drug aflibercept (VEGF Trap) for the second-line treatment of non-small cell lung cancer (NSCLC) showed that adding aflibercept to the chemotherapy dr
Read More »
March 10, 2011
Human Genome Sciences, Inc. and GlaxoSmithKline received approval from the FDA for Benlysta (belimumab) for the treatment of autoantibody-positive systemic lupus erythematosus (SLE) in patients receiving standard therapy.
Read More »
March 9, 2011
Stemline Therapeutics’ lead compound SL-401, has received Orphan Drug designation from FDA for the treatment of acute myeloid leukemia (AML).
Read More »
31 - 45 of 604 results
